Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multi-targeting by monotherapeutic antibacterials.

Lynn L Silver1

  • 1LL Silver Consulting, Springfield, New Jersey 07081, USA. silverly@comcast.net

Nature Reviews. Drug Discovery
|December 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lasso-shaped molecule is a new type of broad-spectrum antibiotic.

Nature·2025
Same author

Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps.

Antimicrobial agents and chemotherapy·2024
Same author

Reply to Kaye and Belley, "Third-Generation Cephalosporin-Resistant <i>Enterobacterales</i> Are Critical Priority Pathogens, Too!"

Antimicrobial agents and chemotherapy·2022
Same author

Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.

Antimicrobial agents and chemotherapy·2022
Same author

Small Molecular Weapons against Multi-Drug Resistance.

Accounts of chemical research·2021
Same author

Setting Our Sights on Infectious Diseases.

ACS infectious diseases·2019
Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026
Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026
Same journal

Designing GPCR-targeted miniproteins.

Nature reviews. Drug discovery·2026
Same journal

Pulsatile FXR agonism.

Nature reviews. Drug discovery·2026
Same journal

CRISPR strategy tackles bacterial toxin.

Nature reviews. Drug discovery·2026
Same journal

Time to peak sales: how long is the climb?

Nature reviews. Drug discovery·2026
See all related articles

Discovering new antibacterial drugs is crucial due to rising resistance. This study explores lessons from existing antibacterial targets to guide the search for novel therapeutics, rather than solely focusing on new targets.

Area of Science:

  • Microbiology and Infectious Diseases
  • Drug Discovery and Development
  • Antimicrobial Resistance

Background:

  • The urgent need for novel antibacterial agents is driven by increasing antimicrobial resistance.
  • Current strategies often focus on identifying novel molecular targets, but these efforts have yielded limited success.
  • Existing antibacterial targets may offer valuable insights for developing new therapeutics.

Purpose of the Study:

  • To re-evaluate the importance of established antibacterial targets in drug discovery.
  • To identify key learnings from 'good old targets' for future antibacterial research.
  • To propose a strategic shift from novel targets to a deeper understanding of existing ones.

Main Methods:

  • Literature review and analysis of historical antibacterial drug discovery successes.

Related Experiment Videos

  • Comparative analysis of established versus hypothetical novel antibacterial targets.
  • Conceptual framework development based on lessons learned from existing targets.

    • Main Results:

    • Novel target-based approaches have faced significant challenges and frustrations in drug development.
    • Established antibacterial targets possess inherent qualities that have historically led to successful therapeutics.
    • A deeper understanding of existing targets can provide a more fruitful path for new antibacterial discovery.

    Conclusions:

    • Rethinking the reliance on novel targets is essential for advancing antibacterial discovery.
    • Leveraging knowledge from 'good old targets' can enhance the efficiency and success rate of developing new antibacterials.
    • A balanced approach, integrating insights from both established and novel targets, may be optimal.